Australian-based Archer Materials has announced the development of a new set of graphene materials that could improve graphene-enhanced biosensing technology. Their work could be game-changing in the field of biosensors, which are capable of detecting life-threatening diseases in much earlier stages, improving the patient survival rate.
“There is no doubt that diseases have a devastating effect on economies and there is value in advancing disease diagnosis using simpler, more accurate biosensors,” Archer CEO Dr Mohammad Choucair told ZDNet. “However, there are only a limited number of materials that can perform [biosensing], and they require innovative development.”
The company says it has been working with Australian biotech commercial advisors to help bring the product to market, develop commercial-grade prototypes and form commercial partnerships domestically and abroad.
The company notes its method could even eliminate the need for using hazardous or non-biocompatible chemicals, which would make the biosensors more effective at screening a broader scope of biomolecules that indicate the early presence of a disease.